Development of therapy for Japanese cedar pollinosis by utilizing reverse-targeting drug delivery system
Project/Area Number |
24790047
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Physical pharmacy
|
Research Institution | University of Shizuoka |
Principal Investigator |
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | ターゲティング / リポソーム / スギ花粉症 / B細胞 / 逆標的化 / Cry j 1 / 胚中心 / ドラッグデリバリーシステム / 膵臓B細胞 / 根治療法 / 脾臓B細胞 |
Outline of Final Research Achievements |
I first succeeded to purify major antigen of Japanese cedar pollinosis, Cry j 1 from Japanese cedar pollen. Then, Cry j 1-modified liposomes were prepared and the targetability of liposomes in Cry j 1-sentitized mice was examined. The results indicated that Cry j 1-modified liposomes were incorporated into the splenic B cells that formed marginal center for antibody production after the systemic injection. Furthermore, when Cry j 1-sensitized mice were treated with doxorubicin-encapsulated Cry j 1-modified liposomes, the production of anti-Cry j 1 IgE antibody following the boosting of Cry j 1 to the mice was significantly suppressed and the allergic symptoms such as sneezing and nasal rubbing were reduced. Notably, the anti-allergic effect was antigen-specific and continued for a long term. These results suggest that the therapeutic strategy utilizing reverse targeting DDS could be useful for the treatment of Japanese cedar pollinosis.
|
Report
(4 results)
Research Products
(22 results)